September 01, 2015; 85 (9) Special Article
Development of the Standards of Reporting of Neurological Disorders (STROND) checklist
A guideline for the reporting of incidence and prevalence studies in neuroepidemiology
Derrick A. Bennett, Carol Brayne, Valery L. Feigin, Suzanne Barker-Collo, Michael Brainin, Daniel Davis, Valentina Gallo, Nathalie Jetté, André Karch, John F. Kurtzke, Pablo M. Lavados, Giancarlo Logroscino, Gabriele Nagel, Pierre-Marie Preux, Peter M. Rothwell, Lawrence W. Svenson
First published July 10, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001866
Derrick A. Bennett
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Carol Brayne
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Valery L. Feigin
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Suzanne Barker-Collo
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Michael Brainin
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Daniel Davis
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Valentina Gallo
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Nathalie Jetté
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
André Karch
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
John F. Kurtzke
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Pablo M. Lavados
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Giancarlo Logroscino
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Gabriele Nagel
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Pierre-Marie Preux
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Peter M. Rothwell
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Lawrence W. Svenson
From the Nuffield Department of Population Health (D.A.B.) and Stroke Prevention Research Unit (P.M.R.), University of Oxford; Department of Public Health and Primary Care (C.B.), University of Cambridge, UK; National Institute for Stroke and Applied Neurosciences (V.L.F.), AUT University, Auckland; Department of Psychology (S.B.-C.), University of Auckland, New Zealand; Department for Clinical Medicine and Preventive Medicine (M.B.), Danube-University, Krems, Austria; Faculty of Population Health Sciences (D.D.), University College London; Centre of Primary Care and Public Health (V.G.), Blizard Institute, Queen Mary, University of London, UK; Department of Clinical Neurosciences and Hotchkiss Brain Institute (N.J.), Department of Community Health Sciences and O'Brien Institute for Public Health, University of Calgary, Canada; Research Group Epidemiological and Statistical Methods (A.K.), Helmholtz Centre for Infection Research, Braunschweig, Germany; Georgetown University (J.F.K.), Washington, DC; Vascular Neurology and Stroke Unit (P.M.L.), Neurology Service, Department of Medicine, Clínica Alemana de Santiago, Universidad del Desarrollo and Department of Neurological Sciences, Universidad de Chile, Institute of Neurosurgery, Santiago; Neurodegenerative Diseases Unit (G.L.), Department of Basic Medicine, Neurosciences and Sense Organs, University Aldo Moro, Bari; Department of Clinical Research in Neurology presso Fondazione Card Panico (G.L.), Tricase (LE), University Aldo Moro, Bari, Italy; Institute of Epidemiology and Medical Biometry (G.N.), University of Ulm, Germany; Institute of Tropical Neurology (P.-M.P.), University of Limoges, France; and School of Public Health (L.W.S.), University of Alberta, Edmonton, Canada.
Development of the Standards of Reporting of Neurological Disorders (STROND) checklist
A guideline for the reporting of incidence and prevalence studies in neuroepidemiology
Derrick A. Bennett, Carol Brayne, Valery L. Feigin, Suzanne Barker-Collo, Michael Brainin, Daniel Davis, Valentina Gallo, Nathalie Jetté, André Karch, John F. Kurtzke, Pablo M. Lavados, Giancarlo Logroscino, Gabriele Nagel, Pierre-Marie Preux, Peter M. Rothwell, Lawrence W. Svenson
Neurology Sep 2015, 85 (9) 821-828; DOI: 10.1212/WNL.0000000000001866
Citation Manager Formats
Make Comment
See Comments
Downloads
2112
Abstract
Background: Incidence and prevalence studies of neurologic disorders play an important role in assessing the burden of disease and planning services. However, the assessment of disease estimates is hindered by problems in reporting for such studies. Despite a growth in published reports, existing guidelines relate to analytical rather than descriptive epidemiologic studies. There are also no user-friendly tools (e.g., checklists) available for authors, editors, and peer reviewers to facilitate best practice in reporting of descriptive epidemiologic studies for most neurologic disorders.
Objective: The Standards of Reporting of Neurological Disorders (STROND) is a guideline that consists of recommendations and a checklist to facilitate better reporting of published incidence and prevalence studies of neurologic disorders.
Methods: A review of previously developed guidance was used to produce a list of items required for incidence and prevalence studies in neurology. A 3-round Delphi technique was used to identify the “basic minimum items” important for reporting, as well as some additional “ideal reporting items.” An e-consultation process was then used in order to gauge opinion by external neuroepidemiologic experts on the appropriateness of the items included in the checklist.
Findings: Of 38 candidate items, 15 items and accompanying recommendations were developed along with a user-friendly checklist.
Conclusions: The introduction and use of the STROND checklist should lead to more consistent, transparent, and contextualized reporting of descriptive neuroepidemiologic studies resulting in more applicable and comparable findings and ultimately support better health care decisions.
GLOSSARY
- GBD=
- Global Burden of Disease and Injuries;
- HIC=
- high-income countries;
- LMIC=
- low- to middle-income countries;
- PD=
- Parkinson disease;
- STROBE=
- Strengthening the Reporting of Observational Studies in Epidemiology;
- STROND=
- Standards of Reporting of Neurological Disorders
Footnotes
↵* These authors are listed in alphabetical order.
Editor's Note: This article was published on June 19, 2015, in the European Journal of Epidemiology and is republished in Neurology with permission. The article was not peer-reviewed by Neurology, and authors' potential conflicts of interest are not disclosed.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received June 6, 2015.
- Accepted in final form June 10, 2015.
- © 2015 American Academy of Neurology
Disputes & Debates: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.